Radius Health Inc. (NASDAQ:RDUS)’s share price fell 2.7% on Tuesday . The company traded as low as $39.10 and last traded at $39.30, with a volume of 213,450 shares. The stock had previously closed at $40.38.

A number of brokerages have recently weighed in on RDUS. Zacks Investment Research upgraded Radius Health from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. Canaccord Genuity restated a “buy” rating on shares of Radius Health in a research note on Tuesday, May 31st. Cowen and Company assumed coverage on Radius Health in a research note on Friday, May 6th. They issued an “outperform” rating on the stock. HC Wainwright assumed coverage on Radius Health in a research note on Monday, May 23rd. They issued a “buy” rating and a $55.00 price objective on the stock. Finally, Goldman Sachs Group Inc. assumed coverage on Radius Health in a research note on Wednesday, March 30th. They issued a “neutral” rating and a $37.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $70.07.

The stock’s 50 day moving average price is $37.77 and its 200 day moving average price is $35.38. The firm’s market cap is $1.68 billion.

Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.94) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.74) by $0.20. During the same quarter last year, the company earned ($0.47) EPS. The company’s quarterly revenue was up .0% compared to the same quarter last year. Equities analysts forecast that Radius Health Inc. will post ($3.71) earnings per share for the current fiscal year.

Other institutional investors have made changes to their positions in the company. Dimensional Fund Advisors LP acquired a new position in shares of Radius Health during the fourth quarter worth $1,362,000. Nationwide Fund Advisors increased its position in shares of Radius Health by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 24,238 shares of the biopharmaceutical company’s stock worth $1,492,000 after buying an additional 437 shares in the last quarter. Rhumbline Advisers increased its position in shares of Radius Health by 12.8% in the fourth quarter. Rhumbline Advisers now owns 31,671 shares of the biopharmaceutical company’s stock worth $1,949,000 after buying an additional 3,585 shares in the last quarter. Swiss National Bank increased its stake in shares of Radius Health by 1.7% in the fourth quarter. Swiss National Bank now owns 36,100 shares of the biopharmaceutical company’s stock valued at $2,222,000 after buying an additional 600 shares during the period. Finally, Mutual of America Capital Management LLC increased its stake in shares of Radius Health by 18.5% in the fourth quarter. Mutual of America Capital Management LLC now owns 36,483 shares of the biopharmaceutical company’s stock valued at $2,245,000 after buying an additional 5,683 shares during the period.

Radius Health, Inc is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, oncology and endocrine diseases. The Company’s lead product candidate is the investigational drug abaloparatide for subcutaneous injection (abaloparatide-SC), which has completed Phase III development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.